Accovion supports local and global projects of all phases and types for the pharmaceutical.

Its providers include research planning and management, scientific monitoring, pharmacovigilance including post-marketing safety, data management, biostatistics, statistical programming, medical writing and electronic publishing. This year 2010, Accovion continuing to grow internationally by establishing two additional subsidiaries in the Czech Republic and in Russia. Related StoriesResearchers successfully restoration nerve cell harm in Alzheimer's dementiaUniversity of Leicester awarded BBSRC grant to explore 3 key areas that influence human healthStudy: Women less likely than males to have good alleviation of chronic pain with long-term opioid useIvana Waller, Chief Operating Officer of Accovion, stated: ‘We’ve been conducting clinical study activities for our customers in the Czech Republic and Russia for some time now.In addition to the patients with melanoma, the 3 individuals with papillary thyroid tumor had a partial or total response, with the response long lasting 8 months in 1 patient and steady disease lasting 11 and 13 months in each of the other 2 patients. A total of 5 patients with metastatic melanoma whose tumors didn’t have a BRAF mutation received doses of 240 mg or more twice daily. None had evidence of tumor regression during the scholarly research; 4 had progressive disease within the first 2 months of treatment. Extension Phase The extension cohort consisted solely of patients who had melanoma with the V600E BRAF mutation. All had been treated at the recommended stage 2 dose of 960 mg twice daily. A complete of 26 of the 32 sufferers had a response , with a complete response in 2 sufferers and a partial response in 24 patients .